# Fulcrum Therapeutics (FULC) — Analyst Forecast

FULC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/fulc/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 0 | 1 | 1 | 2 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Jun 3, 2026 | JP Morgan | Downgraded | Overweight → Underweight | — |
| Jun 2, 2026 | HC Wainwright & Co. | Downgraded | Buy → Neutral | $3.00 |
| Jun 2, 2026 | Leerink Partners | Downgraded | Outperform → Market Perform | $4.00 |
| Jun 2, 2026 | Truist Securities | Downgraded | Buy → Hold | $4.00 |
| Jun 2, 2026 | Piper Sandler | Downgraded | Overweight → Underweight | $3.00 |
| Jun 2, 2026 | Stifel | Downgraded | Buy → Hold | $3.00 |
| Jan 12, 2026 | JP Morgan | Initiated Coverage | Overweight | $20.00 |
| Dec 11, 2025 | Truist Securities | Maintained | Buy | $18.00 |
| Dec 9, 2025 | B of A Securities | Maintained | Underperform | $7.00 |
| Dec 8, 2025 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Dec 8, 2025 | Piper Sandler | Maintained | Overweight | $23.00 |
| Dec 8, 2025 | Cantor Fitzgerald | Maintained | Overweight | $24.00 |
| Dec 8, 2025 | RBC Capital | Maintained | Sector Perform | $10.00 |
| Nov 24, 2025 | HC Wainwright & Co. | Maintained | Buy | $18.00 |
| Nov 24, 2025 | Truist Securities | Initiated Coverage | Buy | $14.00 |
| Oct 30, 2025 | Piper Sandler | Maintained | Overweight | $16.00 |
| Oct 30, 2025 | RBC Capital | Maintained | Sector Perform | $7.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Maintained | Buy | $12.00 |
| Jul 30, 2025 | RBC Capital | Maintained | Sector Perform | $5.00 |
| Jul 29, 2025 | HC Wainwright & Co. | Upgraded | Neutral → Buy | $12.00 |

## Frequently Asked Questions

### Is FULC a buy, sell, or hold?

Analysts covering Fulcrum Therapeutics currently average a Hold rating: 0 buy, 1 hold and 1 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on FULC?

On Jun 3, 2026, JP Morgan downgraded Fulcrum Therapeutics to Underweight.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).